229 related articles for article (PubMed ID: 27913881)
1. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
2. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
[TBL] [Abstract][Full Text] [Related]
3. Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer.
Jeung HC; Rha SY; Shin SJ; Lim SJ; Roh JK; Noh SH; Chung HC
Anticancer Drugs; 2011 Sep; 22(8):801-10. PubMed ID: 21572321
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
7. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
8. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis.
Kim SY; Baek JY; Oh JH; Park SC; Sohn DK; Kim MJ; Chang HJ; Kong SY; Kim DY
Radiat Oncol; 2017 Mar; 12(1):62. PubMed ID: 28347333
[TBL] [Abstract][Full Text] [Related]
10. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1.
Ichikawa W; Takahashi T; Suto K; Shirota Y; Nihei Z; Shimizu M; Sasaki Y; Hirayama R
Int J Cancer; 2006 Oct; 119(8):1927-33. PubMed ID: 16736497
[TBL] [Abstract][Full Text] [Related]
11. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
12. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
[TBL] [Abstract][Full Text] [Related]
13. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.
Kim JY; Shin E; Kim JW; Lee HS; Lee DW; Kim SH; Lee JO; Kim YJ; Kim JH; Bang SM; Ahn SH; Park DJ; Lee JS; Lee JS; Kim HH; Lee KW
PLoS One; 2015; 10(3):e0120324. PubMed ID: 25793299
[TBL] [Abstract][Full Text] [Related]
14. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
15. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
16. High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis.
Wang D; Yu X; Wang X
Int J Biol Markers; 2016 May; 31(2):e101-9. PubMed ID: 27012156
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of combination therapy with oral S-1 and cisplatin in elderly patients with advanced gastric cancer.
Sasaki Y; Iwasa S; Okazaki S; Goto M; Kojima Y; Naganuma A; Nagashima K; Nagai Y; Hirano H; Honma Y; Takashima A; Kato K; Hamaguchi T
Gastric Cancer; 2018 May; 21(3):439-445. PubMed ID: 28766263
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.
Li J; Xu R; Xu J; Denda T; Ikejiri K; Shen L; Toh Y; Shimada K; Kato T; Sakai K; Yamamoto M; Mishima H; Wang J; Baba H
Cancer Sci; 2017 Oct; 108(10):2045-2051. PubMed ID: 28763145
[TBL] [Abstract][Full Text] [Related]
20. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer.
Yamaguchi K; Taniguchi H; Komori A; Narita Y; Nitta S; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K; Mori K; Igarashi Y
BMC Cancer; 2015 Aug; 15():601. PubMed ID: 26311588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]